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Abstract
 
Rationale, aims and objectives
 
For therapy evaluation studies, control groups are some-
times not feasible. In single-arm studies, various bias factors apart from the test therapy can
affect clinical outcomes. The objective of this analysis was to improve the methods to
minimize bias in single-arm studies.
 
Method
 
We present a procedure for combined suppression of several bias factors, using
two methods: sample restriction to patients unaffected by bias, and score adjustment. The
procedure was used for a secondary analysis of disease score (doctors’ global rating, 0–10)
in a cohort of patients receiving anthroposophic therapies for chronic diseases. Four bias
factors were suppressed stepwise: attrition bias (by replacing missing values with the
baseline value carried forward), bias from natural recovery (by sample restriction to
patients with disease duration of 
 
≥
 
12 months), regression to the mean due to symptom-
driven self-selection (by replacing baseline scores with scores three months before enrol-
ment) and bias from adjunctive therapies (by sample restriction to patients not using
adjunctive therapies).
 
Results
 
In the cohort analysed, these four bias factors could together explain a maximum
of 37% of the 0- to 6-month improvement of disease score.
 
Conclusion
 
Combined bias suppression, using sample restriction and score adjustment, is
a transparent procedure to minimize bias in single-arm therapy studies. Further applicabil-
ity of the procedure should be tested in future studies.
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Introduction
 
In therapy evaluation studies, a number of factors apart from the
test therapy can contribute to the outcome, for example, natural
recovery, adjunctive therapies and observation bias. In controlled
studies, the effects of such bias factors can be suppressed by
subtracting the outcome of the control group from the outcome of
the therapy group (with adjustment for baseline differences if the
groups are not randomized). Sometimes, however, control groups
are not feasible, for example, in the case of rare diseases [1],
strong therapy preferences [2] or for ethical reasons [3]. Fifty
years after the introduction of the randomized clinical trial [4],
more than half of published studies even in front-line journals are
not randomized [5] (in surgery more than 90% [6,7]), and for
many therapies (e.g. drugs [8–11], surgery [1,12–14], other proce-
dures [2,15]) the evidence base consists exclusively of studies
without control groups. In reports of single-arm therapy studies,
the issue of therapy effects versus bias is often only brieﬂy men-
tioned, or at the best, the inﬂuence of one or two bias factors is
analysed separately.
This paper contributes to the quality improvement of single-arm
studies by presenting a procedure for combined suppression of
four bias factors that may commonly affect outcomes: attrition
bias, natural recovery, regression to the mean (RTTM) and adjunc-
tive therapies. (The procedure does not encompass other factors
such as placebo effects. However, these factors do not always have
a relevant inﬂuence on clinical outcomes [16,17]. This issue will
be dealt with in a separate paper.)
There are two simple and transparent methods for reliable sup-
pression of individual bias factors without a control group. Each
method has an underlying premise and can be applied if the
premise is fulﬁlled:
 
1
 
If, as a premise, one 
 
necessary precondition for the occurrence
of a certain bias in certain patients
 
 can be identiﬁed on account of
patient characteristics, suppression of this bias is possible by 
 
sam-
ple restriction
 
: the exclusion of patients with the respective char-
acteristics from the study or the analysis, thus restricting the
analysed sample to patients unaffected by this bias.
 
2
 
If, as a premise, the 
 
maximal plausible impact of a certain bias
on the outcome
 
 can be established, suppression of this bias is
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possible by 
 
score adjustment
 
: re-analysis of the outcome after
subtracting the maximum plausible bias impact (analogous to
subtracting the outcome of the control group in a controlled
study).
Technically, both methods of bias suppression are one-way sen-
sitivity analyses, assessing the ‘worst case’ of maximum plausible
bias impact [18]. The objective is thus not to identify the real
magnitude of bias impact (because this magnitude is often
unknown), but to suppress the 
 
maximum plausible
 
 bias impact and
subsequently analyse study outcomes under largely bias-free
conditions.
For simultaneous suppression of several bias factors (techni-
cally a ‘worst case’ extreme scenario analysis [18]), a further
premise is that the techniques used for suppression of each factor
can be combined. The implementation of combined bias suppres-
sion is illustrated in the following.
 
Methods
 
Study sample and outcome measure
 
Combined bias suppression was used for a secondary analysis of
data from the Anthroposophic Medicine Outcome Study (AMOS),
a prospective multicentre cohort study of outpatients aged 1–
75  years starting anthroposophic therapies (art, eurythmy exer-
cises, rhythmical massage or medication) for various chronic dis-
eases. Patients were enrolled from 1998 to 2005. A 2-year analysis
of patients enrolled up to 31 March 2001 had shown signiﬁcant
improvement of disease symptoms and quality of life [19]. Most
improvements occurred during the ﬁrst 6  months after study
enrolment, during which the anthroposophic therapies were
implemented.
The present analysis concerned the 0- to 6-month change of
disease score (doctor’s global assessment of disease severity,
0 
 
=
 
 not present, 10 
 
=
 
 worst possible, documented after 0, 6 and
12 months) and was performed on patients enrolled from 1 July
1998 to 31 March 2001 with disease score available at baseline
(
 
n
 
 
 
=
 
  887 of 898 enrolled patients). The majority of patients
(88.5%, 785/887) were recruited by primary care doctors. Mean
age was 35.6  years (SD 18.5); 73.1% (648/887) were women.
Most frequent main diagnoses, classiﬁed by the International
Classiﬁcation of Diseases, Tenth Edition, were F00-F99 mental
disorders (32.1%, 285/887 patients), M00-M99 musculoskeletal
diseases (19.1%), J00-J99 respiratory diseases (9.0%) and G00-
G99 nervous system disorders (7.0%). Mean disease duration was
6.5 years (SD 8.4).
 
Data analysis
 
Disease score was analysed using a stepwise suppression of four
bias factors: attrition bias, natural recovery, RTTM and adjunctive
therapies. Each subsequent step was added to the previous steps,
provided that the potential impact of the respective bias on the
outcome was found to be positive.
Bias factors may have a potential positive impact on the outcome
(i.e. the suppression of the respective bias reduces the magnitude
of the improvement) or a potential negative impact (suppression
increases the improvement). For bias factors with a potential neg-
ative impact, the ‘worst case’ is zero impact; therefore, the suppres-
sion of such biases was not included in the ﬁnal analysis.
Paired samples were analysed with 
 
t
 
-test, using SPSS 14.01.
 
Step 1: Attrition bias
 
Patient attrition can bias the outcome if patients with missing
outcome data are excluded from the analysis but have less favour-
able results than respondents. This bias can be suppressed by
subtracting its maximum plausible impact on the outcome, that is,
by replacing the missing values with values reﬂecting the maxi-
mum plausible degree to which dropouts may have less favourable
results than respondents. The maximum plausible impact of attri-
tion bias will depend on the individual study situation:
In AMOS, doctors’ 6-month follow-up documentation of dis-
ease score was available for 82.5% of patients (732/887) and
missing for 17.5%. (The corresponding patient 6-month follow-up
documentation was available for 91.4% (811/887) and missing for
8.6%.) Patients with and without available follow-up documenta-
tion did not differ signiﬁcantly in age, sex, diagnosis, disease
duration or baseline disease score. For patients with evaluable data
at 6-month follow-up, disease score was improved from baseline
in 83.5% of patients (611/732), unchanged in 11.6% and deterio-
rated in 4.9%.
The maximum plausible extent of attrition bias was assumed to
be that, in patients with missing values, disease score would be
unchanged from baseline. Accordingly, replacement of missing
values with baseline values should fully suppress attrition bias.
 
Suppression of attrition bias:
 
 To minimize the potential for bias,
missing values were replaced with the baseline value carried
forward.
 
Step 2: Bias from natural recovery
 
Natural recovery (permanent reduction or disappearance of symp-
toms without effective therapy) must be distinguished from RTTM
because of symptom ﬂuctuation and self-selection at symptom
peaks (see Step 3). The potential for natural recovery diminishes
with increasing disease duration and will eventually approach
zero. According to the empirical literature, no relevant improve-
ment will be expected in cohorts with typical AMOS diagnoses
after 1 year’s duration or even earlier. Therefore, restricting the
analysis to patients with disease duration of 
 
≥
 
12 months will sup-
press natural recovery bias. (We searched the literature for meta-
analyses or representative studies of common AMOS diagnoses.
In ﬁve diagnoses investigated, no relevant natural recovery was
found beyond 2–3 months’ duration (low back pain [20], migraine
[21], tension headache [21] and generalized anxiety disorder
[22]) and 12  months’ duration (major depression [23–28]),
respectively.)
 
Suppression of bias from natural recovery:
 
 To minimize the
potential for bias, the sample was restricted to patients with dis-
ease duration of 
 
≥
 
12 months (75.6% of patients, 671/887).
 
Step 3: Bias from regression to the mean
 
In therapy studies of symptomatic patients, RTTM can occur if
symptoms ﬂuctuate and if there is also 
 
symptom-driven patient
self-selection
 
, that is, if patients preferentially seek medical atten- 
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tion and are enrolled into the study at symptom peaks (Fig. 1). As
a consequence of this self-selection, the average disease severity
at study enrolment (in this sample: disease score at 0  months,
DS0) will be higher than the true disease severity (true disease
score). There are three important aspects of this self-selection
bias:
 
•
 
increase of average disease severity before study enrolment
(i.e. 
 
egression from the mean
 
, EFTM);
 
•
 
DS0 showing higher (worse) values than true disease score; and
 
•
 
return to average levels after study enrolment (i.e. RTTM).
The RTTM is a consequence of EFTM, and both will be of the
same magnitude, provided that the amplitude and frequency of
symptom ﬂuctuation do not change over time (Fig. 1).
Another possible cause of RTTM in therapy studies is a 
 
trun-
cated patient selection
 
, which occurs when the inclusion criteria
require a score to exceed a speciﬁc threshold, or when subgroups
are analysed according to cut-off values. Truncated patient selec-
tion did not occur in the present sample, and this issue will not be
further dealt with here.
Regression to the mean from self-selection at symptom peaks
can be suppressed in three ways: by using a concurrent control
group, by complex adjustment techniques [29–32] and by using
two or more baseline scores [33–36]. For the present analysis, we
used two baseline scores: DS0 and DS-3 (disease score 3 months
before study enrolment, documented at study enrolment). DS-3
can be taken as an estimate of true disease score (Fig. 1). There-
fore, replacement of DS0 by DS-3 will suppress RTTM bias (see
Fig. 1).
 
Suppression of RTTM-bias:
 
 To minimize the potential for bias,
DS0 was replaced by DS-3.
(For the present analysis of AMOS patients recruited from 1
July 1998 to 31 March 2001 (AMOS-98-01), a direct replacement
with DS-3 was not possible, because study documentation of DS-
3 had only been performed on AMOS patients recruited from 1
September 2004 to 31 December 2005 (AMOS-04-05). As a
substitute, the difference (DS0 
 
−
 
 DS-3) was calculated in AMOS-
04-05 (average 0.43 points, 
 
n
 
 
 
=
 
 107 patients with disease duration
of 
 
≥
 
12 months). This difference (DS0 
 
−
 
 DS-3 
 
=
 
 EFTM) was then
subtracted from DS0 in AMOS-98-01, in order to estimate DS-3 in
this sample. AMOS-98-01 and AMOS-04-05 patients fulﬁlled the
same eligibility criteria and did not differ signiﬁcantly in age, sex
and main diagnosis. This necessity to impute data from other study
patients is a technical limitation of the present analysis, which can
be avoided in future studies.)
 
Step 4: Bias from adjunctive therapies
 
Adjunctive therapies may affect clinical outcomes. In AMOS,
adjunctive therapies were allowed, and at 6-month follow-up the
patients documented their use of adjunctive therapies during the
ﬁrst six study months (medication use was also documented at 3-
month follow-up). Because AMOS comprised a range of disor-
ders, for which different therapies might affect outcomes, an
analysis of diagnosis-related adjunctive therapies was not feasible
for all diagnoses. The present analysis was therefore performed on
the largest evaluable diagnostic subgroups: patients with a main
diagnosis of mental, respiratory, musculoskeletal or headache
disorders (67.1%, 450 of 671 patients with disease
duration 
 
≥
 
 12 months).
 
Suppression of bias from adjunctive therapies:
 
 To minimize the
potential for bias, this sample was restricted to patients not using
diagnosis-related adjunctive therapies during the ﬁrst 6 months
after study enrolment (54.7% of patients, 246/450). Diagnosis-
related adjunctive therapies were any of the following therapies, if
used for at least 1 day per month:
 
•
 
mental disorders: psychotherapy (in children ergotherapy or
play therapy); anti-epileptic, psycholeptic, analeptic and anti-
addiction drugs (Anatomical Therapeutic Chemical Classiﬁcation
Index N03A, N05-06, N07B);
 
•
 
respiratory disease: relevant respiratory drugs (H02, J01-02,
J04-05, J07A, L03, R01, R03, R06-07) or surgery;
 
•
 
musculoskeletal disease: immunosuppressive, musculoskeletal,
analgesic and antidepressant drugs (L04, M01-05, M09, N02A-B,
N06A); physiotherapy or relevant surgery; and
 
Figure 1
 
Model of egression from the mean (EFTM) and regression to the mean (RTTM) due to symptom-driven patient self-selection. True disease
score (TDS) = DS-3 (disease score 3 months before study enrolment). DS0: disease score at study enrolment.
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•
 
headache disorders: analgesics, antimigraine and antidepressant
drugs (C04AX01, C07AA05, C07AB02, C08CA06, C08DA01,
N02, N03AG01, N06A, N07CA03).
 
Results
 
Each of the bias suppression Steps 1–3 (suppression of attrition
bias, natural recovery and RTTM) leads to a successive reduction
of the 0- to 6-month improvement of disease score (Table  1).
Altogether, Steps 1 
 
+
 
 2 
 
+
 
 3 reduced the average improvement by
37% (2.97 
 
→
 
 1.87 points).
In patients evaluable for Step 4, that is, patients with mental,
respiratory, musculoskeletal or headache disorders, Steps
1 
 
+
 
 2 
 
+
 
 3 resulted in a similar reduction of the improvement by,
altogether, 34% (3.14 
 
→
 
 2.08 points). However, the restriction of
this sample to patients not using diagnosis-related adjunctive ther-
apies (Step 4) leads to a more pronounced improvement of disease
score (2.30 points), compared with the improvement of all patients
with these diagnoses (2.08 points). Thus, the potential impact of
adjunctive therapy bias was not positive but negative. Accordingly,
Step 4 was not included in the ﬁnal analysis.
The ﬁnal analysis of disease score, after suppression of the
maximum plausible positive bias impact by combining
Steps 1 
 
+
 
 2 
 
+
 
 3 in patients with all diagnoses (Fig. 2), showed a
signiﬁcant 0- to 6-month improvement of 1.87 points (95% conﬁ-
dence interval 1.69–2.06 points).
 
Discussion
 
We have presented a procedure for the combined suppression of
four bias factors that may affect outcomes in single-arm studies:
bias from patient attrition, natural recovery, RTTM and adjunc-
tive therapies. The procedure combines two methods: 
 
sample
restriction
 
 (restricting the study sample to patients unaffected by
the respective bias) and 
 
score adjustment
 
 (re-analysis of the out-
come after subtraction of the maximum plausible impact of the
respective bias). The procedure was illustrated by the analysis of
a study of primary care patients with chronic diseases receiving
anthroposophic therapies (AMOS). After combined suppression
of bias from natural recovery and adjunctive therapies (by sample
restriction) and of attrition bias and RTTM (by score adjustment)
it was found that these four bias factors could together explain a
maximum of 37% of the 0- to 6-month improvement of disease
score (0–10), with a residual signiﬁcant improvement of 1.87
points.
 
Table 1
 
Disease score with stepwise bias suppression
Bias suppression steps
 
n
 
0 months
Mean 
 
± 
 
SD
6 months
Mean 
 
± 
 
SD
0–6 months difference 
Mean 95% CI
 
P
 
-value
 
Patients with all diagnoses
 
Patients with evaluable data at 0 and 6 months 732 6.40 
 
± 
 
1.76 3.43 
 
± 
 
2.23 2.97 2.79–3.14
 
P
 
 
 
<
 
 0.001
Step 1: BVCF 887 6.38 
 
± 
 
1.76 3.93 
 
± 
 
2.41 2.45 2.29–2.61
 
P
 
 
 
<
 
 0.001
Step 1 
 
+
 
 2: BVCF, patients with disease duration of
 
≥
 
12 months
671 6.41 
 
± 
 
1.79 4.11 
 
± 
 
2.37 2.30 2.12–2.49
 
P
 
 
 
<
 
 0.001
Final analysis 
 
–
 
 Step 1 
 
+
 
 2 
 
+
 
 3
 
:
 
 BVCF, patients with
disease duration of 
 
≥
 
12 months, adjustment of
baseline score to suppress RTTM
671 5.98 
 
± 
 
1.79 4.11 
 
± 
 
2.37 1.87 1.69–2.06
 
P
 
 
 
<
 
 0.001
 
Patients with mental, respiratory,
 
 
 
musculoskeletal or headache disorders
 
Patients with evaluable data at 0 and 6 months 480 6.36 
 
± 
 
1.71 3.23 
 
± 
 
2.11 3.14 2.92–3.35
 
P
 
 
 
<
 
 0.001
Step 1 
 
+
 
 2 
 
+
 
 3: BVCF; Patients with disease 
duration of 
 
≥
 
12 months, adjustment of baseline
score to suppress RTTM
450 6.00 
 
± 
 
1.72 3.92 
 
± 
 
2.33 2.08 1.85–2.31
 
P
 
 
 
<
 
 0.001
Step 1 
 
+
 
 2 
 
+
 
 3 
 
+
 
 4: BVCF; Patients with disease
duration of 
 
≥
 
12 months, adjustment of baseline
score to suppress RTTM, patients without 
diagnosis-related adjunctive therapies
246 5.95 
 
± 
 
1.68 3.65 
 
± 
 
2.28 2.30 1.99–2.61
 
P
 
 
 
<
 
 0.001
BVCF, missing data replaced by the baseline value carried forward.
RTTM, regression to the mean.
 
Figure 2
 
Disease score without bias suppression and with combined
bias suppression. (Final analysis: suppression of bias from patient attri-
tion, natural recovery and regression to the mean. The additional sup-
pression of adjunctive therapy bias would not further reduce the
improvement). Patients with all diagnoses.
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Although many techniques for bias suppression are known [37],
the simultaneous application of different techniques to suppress
different bias factors within one study does not appear to be widely
used. To our knowledge, the combination of sample restriction and
score adjustment has not been presented previously.
The suppression techniques used here largely fulﬁl the premises
for reliable bias suppression: The premise for 
 
sample restriction
 
 is
that the patients potentially affected by the respective bias can be
identiﬁed and excluded from the study or the analysis. Because
 
adjunctive therapies
 
 can only affect patients who use them, sample
restriction to non-users of diagnosis-related adjunctive therapies
should reliably suppress this potential bias. Bias from 
 
natural
recovery
 
 will be largely excluded by sample restriction to patients
with disease duration of at least 1 year. The reason is that after
1 year’s duration, natural recovery of chronic disease in primary
care does not generally occur. (In ﬁve AMOS indications investi-
gated, no relevant natural recovery is found after follow-up periods
ranging from 2 to 12 months.)
The premise for 
 
score adjustment
 
 is that the maximal plausible
impact of the respective bias can be established and subtracted
from the outcome. For the 6-month analysis of disease score in
AMOS, the maximum plausible impact of 
 
attrition bias
 
 was
assumed to be a no change from baseline in all patients with
missing data – a clearly conservative assumption, as 83% of eval-
uable patients were improved from baseline. The maximum plau-
sible impact of 
 
RTTM bias
 
 from symptom ﬂuctuation and self-
selection at symptom peaks was assumed to equate the full
amount of symptom deterioration observed during the 3 months
preceding study enrolment (DS0 − DS-3). This is probably also a
conservative assumption, as some of this deterioration will not
represent symptom ﬂuctuation but permanent deterioration; for
example, in major depression and in low back pain, higher symp-
tom severity is associated with a more unfavourable prognosis
[38,39].
Thus, the bias suppression techniques used in the present
example were conservative, that is, aimed at protecting against
false-positive results. This principle should be upheld in future
studies.
The advantages of combined bias suppression as presented here
are its transparency and the modular, stepwise procedure, enabling
other researchers to add or delete steps as needed, or to modify
steps, substituting other techniques for the suppression of individ-
ual bias factors.
As an example, to suppress bias from natural recovery, we
restricted the sample according to the criterion of disease duration.
For other studies, the use of this criterion may pose difﬁculties or
be considered insufﬁcient. However, there is a possibility of add-
ing a second criterion: In individual patients with only moderately
long prior disease duration, a short time span between beginning
of treatment and clinically relevant improvement makes spontane-
ous improvement more unlikely than long disease duration alone.
Therefore, a combined criterion (long disease duration and short
time to improvement) may prove more useful than long disease
duration alone.
To suppress bias from adjunctive therapies, we restricted the
sample to non-users of disease-relevant therapies. In other
instances, most or all patients will use adjunctive therapies, mak-
ing sample restriction to non-users unfeasible. However, it may
still be possible to predeﬁne patient groups on a stable adjunctive
therapy regimen (e.g. ongoing use of antidepressants or corticos-
teroids in stable doses), for which the addition of a new therapy
may be assessed.
For minimization of EFTM/RTTM from symptom-driven
patient self-selection, we replaced DS0 with DS-3. This method
has two advantages. First, using DS-3 allows for a direct suppres-
sion of EFTM (which is the primary source of bias in patient self-
selection), instead of suppressing RTTM (which is secondary to
EFTM). Thus, no assumptions of EFTM and RTTM being equal
are needed. Second, no imputing of data from reference groups is
needed nor any assumption about identical score variability of
study sample and reference group. Nonetheless, other researchers
may prefer to use one of the many other techniques for RTTM
adjustment [29–32].
The example of combined bias suppression presented here was
a secondary (post hoc) analysis. In future studies all design and
analysis elements of combined bias suppression can be pre-
planned and incorporated into the study protocol. Thus, several
limitations of the present analysis can be avoided. Regarding nat-
ural recovery, the cut-off point beyond which no relevant recov-
ery will occur can be determined for all indications of interest
(and not just for selected diagnoses, as here). Regarding RTTM,
DS-3 can be documented for each analysed patient (instead of
imputation of data obtained on other study patients, as here).
Adjunctive therapy use can be documented by diaries or week
charts (instead of retrospectively for the last 3–6  months, as
here).
A technical requirement for combined bias suppression is an
adequate sample size, which will depend on the magnitude of the
outcome, the proportion of patients to be excluded from the analy-
sis, the magnitude of patient dropout and so on.
Combined bias suppression has three important general limi-
tations. First, the use of sample restriction means that a direct
conclusion is possible only for the subsample unaffected by bias
(in this analysis, patients with disease duration of ≥12 months
not using adjunctive therapies). No direct conclusions are possi-
ble about the impact of adjunctive therapies in patients using
them or about the impact of natural recovery in patients with
disease duration of <12 months. Notably, this limitation of gen-
eralizability to similar patients receiving similar treatment is in
principle shared by all other empirical evaluations. Second, the
focus on maximum plausible bias impact means that no conclu-
sions are possible about the minimum plausible, or the true bias
impact. Thus, in the analysed sample, the four biases suppressed
could together explain a maximum of 37% of the improvement.
However, their true impact may have been 0% (even a negative
impact is possible, as was found in the case of adjunctive thera-
pies), but this issue was not the subject of the analysis. Third,
and more important, combined bias suppression only covers the
bias factors expressly suppressed – in the present example four
factors – and not other confounders (e.g. patient expectations
[40] or observation bias [41]) that can also affect clinical out-
comes. The method of combined bias suppression should there-
fore be supplemented with a method for the identiﬁcation of all
potentially relevant bias factors and the assessment of their rele-
vance for the respective outcome (Hamre et al., manuscript in
preparation). Depending on study characteristics (patients, indi-
cations, treatment, outcomes, etc.), different bias factors may or
may not be relevant.928 © 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
Bias suppression H.J. Hamre et al.
Conclusion
Combined bias suppression, using sample restriction and score
adjustment, is a straightforward and transparent procedure for
minimization of bias in single-arm therapy studies. The procedure
should be tested in future studies.
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